DK2035581T3 - Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf - Google Patents

Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf

Info

Publication number
DK2035581T3
DK2035581T3 DK07796305.6T DK07796305T DK2035581T3 DK 2035581 T3 DK2035581 T3 DK 2035581T3 DK 07796305 T DK07796305 T DK 07796305T DK 2035581 T3 DK2035581 T3 DK 2035581T3
Authority
DK
Denmark
Prior art keywords
fap
procedures
against tumor
composition against
dna composition
Prior art date
Application number
DK07796305.6T
Other languages
English (en)
Inventor
Ralph A Reisfeld
Markus Loeffler
Joerg A Krueger
Andreas G Niethammer
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK2035581T3 publication Critical patent/DK2035581T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK07796305.6T 2006-06-21 2007-06-21 Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf DK2035581T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81531606P 2006-06-21 2006-06-21
PCT/US2007/014440 WO2007149518A2 (en) 2006-06-21 2007-06-21 Dna composition against tumor stromal antigen fap and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2035581T3 true DK2035581T3 (da) 2012-10-08

Family

ID=38834119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07796305.6T DK2035581T3 (da) 2006-06-21 2007-06-21 Dna-sammensætning mod tumorstromaantigen fap og fremgangsmåder til anvendelse deraf

Country Status (10)

Country Link
US (1) US20090253778A1 (da)
EP (1) EP2035581B1 (da)
JP (1) JP2009541328A (da)
CN (1) CN101506381B (da)
CA (1) CA2657217A1 (da)
DK (1) DK2035581T3 (da)
ES (1) ES2393372T3 (da)
PL (1) PL2035581T3 (da)
PT (1) PT2035581E (da)
WO (1) WO2007149518A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
SG11201400250UA (en) * 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
BR112019005513A2 (pt) * 2016-09-21 2019-06-11 Univ Pennsylvania composição imunogênica, molécula de ácido nucleico, peptídeo, e, métodos para induzir uma resposta imune contra proteína de ativação de fibroblasto e para tratar ou prevenir uma patologia associada a tumor.
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN112402597B (zh) * 2020-11-26 2022-04-01 四川大学 一种fap修饰的类外泌体纳米囊泡肿瘤疫苗
US20240115670A1 (en) * 2021-01-27 2024-04-11 Georgetown University Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration
CN114561387B (zh) * 2022-02-28 2023-08-15 北京大学现代农业研究院 花生启动子及其应用
CN118894923A (zh) * 2024-07-11 2024-11-05 北京鸿岑生物科技有限公司 一种tcr-t及其制备方法以及在制备治疗肿瘤药物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846910B2 (en) * 1994-04-20 2005-01-25 Ludwig Institute For Cancer Research Isolated proteins containing portions of FAPα and other proteins
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US20030157534A1 (en) * 2001-12-26 2003-08-21 Manuel Engelhorn DNA immunization with libraries of minigenes encoding degenerate variants of major histocompatability class l restricted epitopes
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
CA2478063A1 (en) * 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
BRPI0408774A (pt) * 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
EP1784645A2 (en) * 2004-07-29 2007-05-16 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with fibroblast activation protein

Also Published As

Publication number Publication date
PL2035581T3 (pl) 2013-01-31
ES2393372T3 (es) 2012-12-20
CN101506381A (zh) 2009-08-12
EP2035581A2 (en) 2009-03-18
EP2035581B1 (en) 2012-09-26
WO2007149518A3 (en) 2008-11-13
PT2035581E (pt) 2012-12-06
EP2035581A4 (en) 2010-01-20
US20090253778A1 (en) 2009-10-08
CA2657217A1 (en) 2007-12-27
WO2007149518A2 (en) 2007-12-27
CN101506381B (zh) 2012-09-05
JP2009541328A (ja) 2009-11-26

Similar Documents

Publication Publication Date Title
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
NO20200671A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
DK2107905T3 (da) Fast sammensætning omfattende alogliptin og pioglitazon
DE602007013436D1 (de) N-methylaminomethyl-isoindol-verbindungen und diese enthaltende zusammensetzungen und diese verwendende verfahren
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2320911T3 (da) Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2056964T3 (da) Hidtil ukendt molekylsigtesammensætning, fremgangsmåde til fremstilling deraf og fremgangsmåde til anvendelse deraf
PL2578081T3 (pl) Kompozycje, sposoby i urządzenia do leczenia chorób wątroby
DK2066817T3 (da) Molekylære afbrydere og fremgangsmåder til anvendelse deraf
DK1760156T3 (da) Materialer og fremgangsmåder til effektiv mælkesyrefremstilling
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
PL2035581T3 (pl) Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania
DK2036543T3 (da) Granulat og fremgangsmåde til fremstilling deraf
DK2190665T3 (da) Kompositorgan og fremgangsmåde til dets fremstilling
DE602006020089D1 (de) Verfahren zur CVI
DK1986508T3 (da) Fremgangsmåder og sammensætninger til behandling af felin hyperthyroidisme
BRPI0807903A2 (pt) Composições medicinais melhoradas compreendendo buprenorfina e nalmefeno.